Kirik D - Search Results

1

Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons.

Ulusoy A, Sahin G, Björklund T, Aebischer P, Kirik D. Ulusoy A, et al. Among authors: kirik d. Mol Ther. 2009 Sep;17(9):1574-84. doi: 10.1038/mt.2009.142. Epub 2009 Jul 7. Mol Ther. 2009. PMID: 19584816 Free PMC article.

2

Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy.

Carlsson T, Björklund T, Kirik D. Carlsson T, et al. Among authors: kirik d. Curr Gene Ther. 2007 Apr;7(2):109-20. doi: 10.2174/156652307780363125. Curr Gene Ther. 2007. PMID: 17430130 Review.

3

Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.

Ulusoy A, Sahin G, Kirik D. Ulusoy A, et al. Among authors: kirik d. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13159-64. doi: 10.1073/pnas.1003432107. Epub 2010 Jul 6. Proc Natl Acad Sci U S A. 2010. PMID: 20615977 Free PMC article.

4

Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease.

Cederfjäll E, Sahin G, Kirik D, Björklund T. Cederfjäll E, et al. Among authors: kirik d. Mol Ther. 2012 Jul;20(7):1315-26. doi: 10.1038/mt.2012.1. Epub 2012 Jan 31. Mol Ther. 2012. PMID: 22294150 Free PMC article.

5

Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.

Ulusoy A, Björklund T, Buck K, Kirik D. Ulusoy A, et al. Among authors: kirik d. Neurobiol Dis. 2012 Sep;47(3):367-77. doi: 10.1016/j.nbd.2012.05.012. Epub 2012 May 31. Neurobiol Dis. 2012. PMID: 22659302

6

In vivo gene delivery for development of mammalian models for Parkinson's disease.

Ulusoy A, Bjorklund T, Hermening S, Kirik D. Ulusoy A, et al. Among authors: kirik d. Exp Neurol. 2008 Jan;209(1):89-100. doi: 10.1016/j.expneurol.2007.09.011. Epub 2007 Sep 22. Exp Neurol. 2008. PMID: 18028909 Review.

7

Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease?

Ulusoy A, Kirik D. Ulusoy A, et al. Among authors: kirik d. Exp Neurol. 2008 Aug;212(2):258-60. doi: 10.1016/j.expneurol.2008.04.026. Epub 2008 May 3. Exp Neurol. 2008. PMID: 18538324 Review.

8

Applications of lentiviral vectors for biology and gene therapy of neurological disorders.

Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N, Kirik D. Lundberg C, et al. Among authors: kirik d. Curr Gene Ther. 2008 Dec;8(6):461-73. doi: 10.2174/156652308786847996. Curr Gene Ther. 2008. PMID: 19075629 Review.

9

Scientific rationale for the development of gene therapy strategies for Parkinson's disease.

Björklund T, Kirik D. Björklund T, et al. Among authors: kirik d. Biochim Biophys Acta. 2009 Jul;1792(7):703-13. doi: 10.1016/j.bbadis.2009.02.009. Epub 2009 Feb 27. Biochim Biophys Acta. 2009. PMID: 19254760 Free article. Review.

10

Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.

Björklund T, Hall H, Breysse N, Soneson C, Carlsson T, Mandel RJ, Carta M, Kirik D. Björklund T, et al. Among authors: kirik d. J Neurochem. 2009 Oct;111(2):355-67. doi: 10.1111/j.1471-4159.2009.06340.x. Epub 2009 Aug 17. J Neurochem. 2009. PMID: 19686242 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters